Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-06-16

Small ligands to interfere with Thymidylate synthase dimer formation as new tools for development of anticancer agents against ovarian carcinoma

Objective

Ovarian cancer is the fifth most common cause of death from cancer in women. The standard firstline treatment is a combination of paclitaxel and carboplatin (DDP) or carboplatin alone. Age, performance status and treatment preferences of the individual patient help in selecting single or combination therapy. In the case of progressive disease or drug resistance treatment with platinum, either alone or in combination, especially investigational compounds should be used. Themechanisms behind acquired resistance to cDDP and its derivatives are not clear yet, although it is evident that the process is multifactorial including, enhanced DNA repair. In the human ovarian carcinoma cell line A2780, a 3-fold-DDP-resistance was associated with cross-resistance to the thymidylate synthase (TS) inhibitor 5-fluorouracil and to methotrexate, a 2.5-fold increase in TS, and an increase in the intracellular pools of the TS cofactor 5, 10-methylentetrahydrofolate and of tetrahydrofolate. The ultimate goal of LIGHTS is to directly halt tumour progression and the development of drug resistance upon treatment with platinum derived drugs by inhibiting the protein regulatory function of monomeric TS through small molecule cellular perturbation. The scientific and technological objectives will be to design small-ligand libraries to bind to the TS monomer (dimer interface) and thereby disrupt TS.
The strategy will include, protein system analysis, protein labelling to identify low-affinity ligands, peptide mimic design & synthesis, and filtering for ADME properties. The multidisciplinary approach will be carried out by a consortium integrating Molecular modelling, Chemistry, Chemoinformatics, Structural Biology and Pharmacology, and will apply the knowledge being created by genomics and other fields of basic research the problem of discovery of anticancer agents. The consortium consists of six groups from five different countries, including three SMEs.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

You need to log in or register to use this function

Call for proposal

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Coordinator

UNIVERSITY OF MODENA AND REGGIO EMILIA
EU contribution
No data
Address
Via Campi 183
MODENA
Italy

See on map

Total cost
No data

Participants (5)